| Amanda Elizabeth Skiftun, MD | |
|
5225 23rd Ave S, Fargo, ND 58104-7927 | |
| (701) 417-6428 | |
| Not Available |
| Full Name | Amanda Elizabeth Skiftun |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 10 Years |
| Location | 5225 23rd Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649682253 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Different types of dementia show dissimilar changes in brain activity. A network mapping technique described in the open access journal BMC Neuroscience has been applied to EEG data obtained from patients with Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD, a less common type of dementia with more prominent behavioral symptoms).
Nearly two-thirds of the herbal medicines used by cancer patients in the Middle East have potential health risks, according to a new survey led by Assistant Professor Eran Ben-Arye, of the Technion-Israel Institute of Technology.
› Verified 5 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Different types of dementia show dissimilar changes in brain activity. A network mapping technique described in the open access journal BMC Neuroscience has been applied to EEG data obtained from patients with Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD, a less common type of dementia with more prominent behavioral symptoms).
Nearly two-thirds of the herbal medicines used by cancer patients in the Middle East have potential health risks, according to a new survey led by Assistant Professor Eran Ben-Arye, of the Technion-Israel Institute of Technology.
› Verified 5 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Different types of dementia show dissimilar changes in brain activity. A network mapping technique described in the open access journal BMC Neuroscience has been applied to EEG data obtained from patients with Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD, a less common type of dementia with more prominent behavioral symptoms).
Nearly two-thirds of the herbal medicines used by cancer patients in the Middle East have potential health risks, according to a new survey led by Assistant Professor Eran Ben-Arye, of the Technion-Israel Institute of Technology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Elizabeth Skiftun, MD 2438 N Pond Dr E, West Fargo, ND 58078-7840 Ph: (701) 307-0883 | Amanda Elizabeth Skiftun, MD 5225 23rd Ave S, Fargo, ND 58104-7927 Ph: (701) 417-6428 |
News Archive
Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
Different types of dementia show dissimilar changes in brain activity. A network mapping technique described in the open access journal BMC Neuroscience has been applied to EEG data obtained from patients with Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD, a less common type of dementia with more prominent behavioral symptoms).
Nearly two-thirds of the herbal medicines used by cancer patients in the Middle East have potential health risks, according to a new survey led by Assistant Professor Eran Ben-Arye, of the Technion-Israel Institute of Technology.
› Verified 5 days ago
Dr. Latif Sean Ougzin, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 Fax: 701-364-8078 | |
Manuel A. Colon-dejesus, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 701-234-5621 | |
John V Vinych, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 Fax: 701-364-8078 | |
Patrick J. Indergaard, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 701-234-6258 Fax: 701-234-7334 | |
Shelby Suzanne Best, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 | |
Layne Egan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5225 23rd Ave S, Fargo, ND 58104 Phone: 701-417-2575 | |
Alanna Velo, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 218-205-7365 |